Cyberonics competitors

Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Tom McCourt joined Ironwood as chief commercial officer and senior vice president of marketing and sales in 2009. He was drawn to Ironwood by the quality and values of the people and by the potential he saw in our first product. Since coming on board, Tom has designed and implemented Ironwood’s commercial strategy, leading the hiring of a sales force and bringing our first medicine to patients. Prior to joining Ironwood, Tom led the U.S. brand team for denosumab at Amgen Inc. Before that, he held a number of senior commercial roles with Novartis AG, where he directed the launch and growth of Zelnorm® (tegaserod maleate) for the treatment of patients with IBS‐C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Tom was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec® (omeprazole). He has a degree in pharmacy from the University of Wisconsin.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.

Dr. William Carson H. is a President and Chief Executive Officer at Otsuka America Pharmaceutical, Inc. and is based in United States.

Fulvio Renoldi Bracco is a Chief Executive Officer at Acist Medical Systems and Head:Global Business Unit at Bracco Group. He works or has worked as Board Member at Esaote Spa and Head:Global Business at Alfio Bardolla Training.